每經AI快(kuai)訊，南微(wei)(wei)醫(yi)學（SH 688029，收(shou)盤(pan)價：87元）11月21日(ri)(ri)(ri)晚(wan)間(jian)發布公(gong)(gong)(gong)(gong)告稱，截至本(ben)公(gong)(gong)(gong)(gong)告日(ri)(ri)(ri)，深圳(zhen)市(shi)中(zhong)(zhong)(zhong)科招商創(chuang)業投資有限公(gong)(gong)(gong)(gong)司(si)(si)(si)持(chi)有南微(wei)(wei)醫(yi)學科技股(gu)(gu)(gu)份(fen)(fen)(fen)(fen)有限公(gong)(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)份(fen)(fen)(fen)(fen)約(yue)4225萬股(gu)(gu)(gu)，占公(gong)(gong)(gong)(gong)司(si)(si)(si)總股(gu)(gu)(gu)本(ben)的(de)約(yue)22.56%。相(xiang)關(guan)股(gu)(gu)(gu)份(fen)(fen)(fen)(fen)來源為公(gong)(gong)(gong)(gong)司(si)(si)(si)首次公(gong)(gong)(gong)(gong)開發行(xing)股(gu)(gu)(gu)票并上市(shi)前取(qu)得的(de)股(gu)(gu)(gu)份(fen)(fen)(fen)(fen)，及該等(deng)股(gu)(gu)(gu)份(fen)(fen)(fen)(fen)于(yu)公(gong)(gong)(gong)(gong)司(si)(si)(si)2022年實(shi)施資本(ben)公(gong)(gong)(gong)(gong)積轉(zhuan)(zhuan)增(zeng)股(gu)(gu)(gu)本(ben)時(shi)獲得股(gu)(gu)(gu)份(fen)(fen)(fen)(fen)，相(xiang)關(guan)股(gu)(gu)(gu)份(fen)(fen)(fen)(fen)已于(yu)2022年7月22日(ri)(ri)(ri)起(qi)上市(shi)流通(tong)。公(gong)(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)東(dong)中(zhong)(zhong)(zhong)科招商因自身(shen)資金(jin)需(xu)求，擬(ni)通(tong)過上海證券交(jiao)易(yi)所交(jiao)易(yi)系統以集(ji)中(zhong)(zhong)(zhong)競價、大宗(zong)交(jiao)易(yi)方式(shi)減持(chi)公(gong)(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)份(fen)(fen)(fen)(fen)合計不(bu)超過約(yue)562萬股(gu)(gu)(gu)，其中(zhong)(zhong)(zhong)擬(ni)通(tong)過證券交(jiao)易(yi)所集(ji)中(zhong)(zhong)(zhong)競價交(jiao)易(yi)方式(shi)進行(xing)減持(chi)的(de)，將(jiang)(jiang)于(yu)減持(chi)計劃公(gong)(gong)(gong)(gong)告披(pi)露(lu)之(zhi)日(ri)(ri)(ri)起(qi)15個交(jiao)易(yi)日(ri)(ri)(ri)之(zhi)后的(de)90日(ri)(ri)(ri)內(nei)減持(chi)公(gong)(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)份(fen)(fen)(fen)(fen)不(bu)超過約(yue)187萬股(gu)(gu)(gu)；擬(ni)通(tong)過大宗(zong)交(jiao)易(yi)方式(shi)減持(chi)的(de)，將(jiang)(jiang)于(yu)本(ben)減持(chi)計劃披(pi)露(lu)之(zhi)日(ri)(ri)(ri)起(qi)3個交(jiao)易(yi)日(ri)(ri)(ri)之(zhi)后的(de)90日(ri)(ri)(ri)內(nei)減持(chi)公(gong)(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)份(fen)(fen)(fen)(fen)不(bu)超過約(yue)374萬股(gu)(gu)(gu)。本(ben)次擬(ni)通(tong)過以上兩種方式(shi)減持(chi)的(de)股(gu)(gu)(gu)份(fen)(fen)(fen)(fen)合計不(bu)超過公(gong)(gong)(gong)(gong)司(si)(si)(si)總股(gu)(gu)(gu)本(ben)比例的(de)3%。若減持(chi)期間(jian)公(gong)(gong)(gong)(gong)司(si)(si)(si)有送股(gu)(gu)(gu)、資本(ben)公(gong)(gong)(gong)(gong)積金(jin)轉(zhuan)(zhuan)增(zeng)股(gu)(gu)(gu)本(ben)等(deng)股(gu)(gu)(gu)份(fen)(fen)(fen)(fen)變動事項，減持(chi)股(gu)(gu)(gu)份(fen)(fen)(fen)(fen)數量進行(xing)相(xiang)應調整。

2021年1至12月份，南微醫學的(de)營業收入構(gou)成為(wei)：醫療器(qi)械占比(bi)99.76%。

南微醫學(xue)的(de)董事長是隆(long)曉輝，男，63歲(sui)，學(xue)歷背(bei)景為碩士；總經理是冷德嶸，男，59歲(sui)，學(xue)歷背(bei)景為本科(ke)。

截至發稿(gao)，南微醫學(xue)市值為163億元(yuan)。

道達號（daoda1997）“個股(gu)趨勢”提醒：
1. 近30日內共有1批機構對南微醫學調研，合計調研的機構家數為116家；
2. 南微醫學上次發布減持公告是2022年11月15日，第二個交易日下跌1.79%，南微醫學近一年共發布10次減持類公告。
更多個股(gu)趨勢信(xin)息，請搜索微(wei)信(xin)公(gong)眾(zhong)號(hao)(hao)“道達號(hao)(hao)”，回復“查詢(xun)”，領取免費查詢(xun)權(quan)限！

每經(jing)頭條（nbdtoutiao）——

(記者 蔡鼎)

免(mian)責聲明：本文內容與數據僅(jin)供(gong)參考，不構成投資建議，使用前請核實。據此(ci)操(cao)作(zuo)，風險自擔(dan)。